Opinion|Videos|June 20, 2024

EV-302: Patient-Reported Outcomes from EV+Pembro in mUC

Author(s)Rahul Gosain, MD, Rohit Gosain, MD, Toni K. Choueiri, MD

Following ASCO 2024, Toni Choueiri, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent updates from the EV-302 study investigating enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

Episodes in this series

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 1 EV-302: Patient-Reported Outcomes from EV+Pembro in mUC

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 2 The Role of ctDNA in Genitourinary Cancer

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 3 KIM-1: Biomarker Analysis in IMmotion010 in RCC

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 4 Real-World Evidence from the IMDC

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

EP. 5 PSMAfore: Health-Related QoL and Pain in Taxane-Naïve Patients with mCRPC

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices

September 28th, 2026

Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices

Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Denosumab Biosimilar Approved For Existing Oncology Indications

Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC

FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026

Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer

New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC